Tempus AI (TEM) Expected to Post Earnings on Thursday

Tempus AI (NASDAQ:TEM) will likely be issuing its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $379.6680 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same quarter in the prior year, the company posted ($0.24) earnings per share. Tempus AI’s revenue for the quarter was up 36.1% compared to the same quarter last year. On average, analysts expect Tempus AI to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tempus AI Stock Down 4.1%

Tempus AI stock opened at $46.96 on Thursday. Tempus AI has a 1-year low of $41.73 and a 1-year high of $104.32. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. The stock has a market cap of $8.43 billion, a PE ratio of -27.30 and a beta of 3.46. The stock’s fifty day moving average is $51.66 and its two-hundred day moving average is $53.76.

Insider Buying and Selling

In other Tempus AI news, EVP Andrew Polovin sold 8,703 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $383,541.21. Following the completion of the sale, the executive vice president directly owned 128,215 shares of the company’s stock, valued at $5,650,435.05. This represents a 6.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $46.70, for a total value of $7,763,875.00. Following the sale, the chief executive officer directly owned 8,808,533 shares of the company’s stock, valued at $411,358,491.10. The trade was a 1.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 616,043 shares of company stock worth $31,748,593. Insiders own 24.26% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently modified their holdings of the stock. ARK Investment Management LLC grew its position in Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after buying an additional 381,816 shares during the last quarter. State Street Corp raised its position in Tempus AI by 9.8% during the 4th quarter. State Street Corp now owns 1,616,338 shares of the company’s stock worth $95,445,000 after buying an additional 143,676 shares during the last quarter. Voloridge Investment Management LLC raised its position in Tempus AI by 183.0% during the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after buying an additional 1,039,176 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Tempus AI by 0.4% in the 3rd quarter. Franklin Resources Inc. now owns 1,456,120 shares of the company’s stock worth $117,523,000 after acquiring an additional 5,375 shares during the period. Finally, AQR Capital Management LLC lifted its stake in shares of Tempus AI by 6.4% in the 3rd quarter. AQR Capital Management LLC now owns 904,872 shares of the company’s stock worth $73,032,000 after acquiring an additional 54,692 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus announced a national launch of OneOme pharmacogenomics testing, expanding its precision-medicine offerings and potentially improving patient safety and future revenue growth. Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine
• Positive Sentiment: Needham & Company reaffirmed a Buy rating on Tempus AI, signaling continued analyst confidence despite recent weakness. Needham & Company LLC Reaffirms Buy Rating for Tempus AI (NASDAQ:TEM)
• Neutral Sentiment: Analyst commentary on Tempus AI and other healthcare names offered additional context, but did not appear to materially change the investment thesis. Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and 4D Molecular Therapeutics (FDMT)
• Negative Sentiment: Investor focus on Tempus’ large Personalis acquisition may be weighing on the stock, as the deal is expensive and could pressure margins or increase leverage before synergies are realized. Tempus AI (TEM) On Its Personalis Deal And Whether The Bull Case Is Priced In

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on TEM. Freedom Capital raised Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. Wall Street Zen cut Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Guggenheim upped their price target on Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Jefferies Financial Group assumed coverage on Tempus AI in a report on Monday, April 13th. They issued an “underperform” rating and a $35.00 price target for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price target on shares of Tempus AI in a research note on Monday. Nine analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $68.92.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.